Theravance Biopharma Q1 2024 GAAP EPS $(0.24) Beats $(0.25) Estimate, Sales $14.503M Beat $13.963M Estimate

5/13/24 4:13:23 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TBPH alert in real time by email

Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.25) by 4 percent. The company reported quarterly sales of $14.503 million which beat the analyst consensus estimate of $13.963 million by 3.87 percent. This is a 39.22 percent increase over sales of $10.417 million the same period last year.

Get the next $TBPH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TBPH

Date	Price Target	Rating	Analyst
8/6/2024	$15.00 → $10.00	Outperform → Market Perform	Leerink Partners
4/12/2024	$21.00	Buy	BTIG Research
1/8/2024		Outperform → In-line	Evercore ISI
5/23/2022	$12.00	Outperform	SVB Leerink
3/2/2022	$10.00 → $11.00	Underweight	Morgan Stanley
2/24/2022	$8.00 → $12.00	Buy	HC Wainwright & Co.
11/5/2021	$7.00 → $12.00	Underweight → Neutral	JP Morgan
9/16/2021	$14.00 → $10.00	Underweight	Morgan Stanley

More analyst ratings

$TBPH
Press Releases

Fastest customizable press release news feed in the world

Theravance Biopharma to Participate in an Upcoming Investor Conference
DUBLIN, Nov. 20, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 11:15 am EST (8:15 am PST/4:15 pm GMT) and will be hosting in-person meetings with the investment community at the conference. Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company's website for 30 days. About Theravance Biopharma Theravance Biopharma, Inc.'s focus is to
11/20/24 6:00:00 AM ET
$TBPH
Biotechnology: Pharmaceutical Preparations
Health Care
Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value
Third quarter results highlight strong operational performance across key value drivers:YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris, an all-time high, increased 7% versus Q3 2023 and 14% versus Q2 20241CYPRESS enrollment in-line with expectations, with timelines on trackTRELEGY net sales increased 17%, to $789 million, as reported by GSK:Q4 sales of at least ~$260 million needed to earn $25 million milestone2Q4 sales of at least ~$610 million needed to earn $50 million milestone2Board of Directors announces initiatives to unlock shareholder value and enhance corporate governanceDUBLIN, Nov. 12, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharm
11/12/24 4:05:00 PM ET
$TBPH
Biotechnology: Pharmaceutical Preparations
Health Care
Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024
DUBLIN, Oct. 24, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its third quarter 2024 financial results and provide a business update after market close on Tuesday, November 12, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.c
10/24/24 6:00:00 AM ET
$TBPH
Biotechnology: Pharmaceutical Preparations
Health Care

$TBPH
Financials

Live finance-specific insights

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value
Third quarter results highlight strong operational performance across key value drivers:YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris, an all-time high, increased 7% versus Q3 2023 and 14% versus Q2 20241CYPRESS enrollment in-line with expectations, with timelines on trackTRELEGY net sales increased 17%, to $789 million, as reported by GSK:Q4 sales of at least ~$260 million needed to earn $25 million milestone2Q4 sales of at least ~$610 million needed to earn $50 million milestone2Board of Directors announces initiatives to unlock shareholder value and enhance corporate governanceDUBLIN, Nov. 12, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharm
11/12/24 4:05:00 PM ET
$TBPH
Biotechnology: Pharmaceutical Preparations
Health Care
Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024
DUBLIN, Oct. 24, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its third quarter 2024 financial results and provide a business update after market close on Tuesday, November 12, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.c
10/24/24 6:00:00 AM ET
$TBPH
Biotechnology: Pharmaceutical Preparations
Health Care
Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Q2 2024 YUPELRI® (revefenacin) net sales of $54.5 million, recognized by Viatris, decreased 1% from Q2 20231Viatris collaboration revenue of $14.3 million, increased 4% versus Q2 2023Partner Viatris submitted YUPELRI NDA in China; $7.5 million milestone if approvedNow expecting last patient into the open label portion of CYPRESS in mid-2025, top line data anticipated approximately 6 months laterQ2 2024 TRELEGY net sales of $1.065 billion, increasing the likelihood of achieving up to $50 million of milestones in 2024Q2 2024 ending cash balance of $96.1 millionDUBLIN, Aug. 5, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced
8/5/24 4:05:00 PM ET
$TBPH
Biotechnology: Pharmaceutical Preparations
Health Care

$TBPH
Leadership Updates

Live Leadership Updates

Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors
Enters into Cooperation Agreement with Shareholder Irenic Capital Reaffirms Intention to Return All Excess Capital to Shareholders and MaximizeShareholder Value DUBLIN, Dec. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ:TBPH) today announced the appointment to its Board of Directors of Jeremy Grant, who serves as a Special Advisor to Irenic Capital Management LP ("Irenic"). With the addition of Mr. Grant, Theravance has appointed four new directors to the Board since 2020. "We are pleased to welcome Jeremy to the Theravance Board a
12/21/23 5:00:00 PM ET
$TBPH
Biotechnology: Pharmaceutical Preparations
Health Care
Irenic Welcomes the Appointment of a Shareholder Representative to Theravance Biopharma's Board of Directors
Believes Jim Kelly of Weiss Asset Management Will Bring Important Ownership Mentality to the Boardroom Encourages the Board to Continue Taking Concrete Steps to Improve Capital Allocation, Enhance Corporate Governance and Review Strategic Alternatives Irenic Capital Management, LP (together with its affiliates, "Irenic" or "we"), a top shareholder of Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance" or the "Company"), today issued the following statement regarding the Company's appointment of Jim Kelly, Managing Director at Weiss Asset Management, to the Board of Directors (the "Board"): "Irenic welcomes the appointment of Jim Kelly to the Theravance Board. We respect and admire
4/12/23 7:00:00 AM ET
$TBPH
Biotechnology: Pharmaceutical Preparations
Health Care
Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors
DUBLIN, April 11, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced the appointment of Jim Kelly, Managing Director at Weiss Asset Management, the Company's second largest shareholder, to its Board of Directors. With the appointment of Mr. Kelly, four new directors have joined the Company's Board of Directors since 2018 as part of its ongoing board refreshment process. "We are pleased to welcome Jim Kelly to the Theravance Board of Directors. Weiss Asset Management has been one of our largest shareholders si
4/11/23 4:05:00 PM ET
$TBPH
Biotechnology: Pharmaceutical Preparations
Health Care

Theravance Biopharma Q1 2024 GAAP EPS $(0.24) Beats $(0.25) Estimate, Sales $14.503M Beat $13.963M Estimate

Chat with this insight

Recent Analyst Ratings for $TBPH

$TBPH Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Samaha Eli bought $7,798,440 worth of COM (999,800 units at $7.80) (SEC Form 4)

Samaha Eli bought $13,117,335 worth of COM (1,499,124 units at $8.75) (SEC Form 4)

$TBPH Press Releases

Fastest customizable press release news feed in the world

Theravance Biopharma to Participate in an Upcoming Investor Conference

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value

Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024

$TBPH Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Theravance Biopharma Inc.

Amendment: SEC Form SC 13G/A filed by Theravance Biopharma Inc.

Amendment: SEC Form SC 13G/A filed by Theravance Biopharma Inc.

$TBPH Financials

Live finance-specific insights

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value

Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024

Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

$TBPH Market Insights

Live Market Insights

Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $20 Price Target

HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $20 Price Target

$TBPH SEC Filings

SEC Form 10-Q filed by Theravance Biopharma Inc.

Theravance Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Theravance Biopharma Inc. filed SEC Form 8-K: Other Events

$TBPH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF EXECUTIVE OFFICER Winningham Rick E covered exercise/tax liability with 15,997 units of Ordinary Shares, decreasing direct ownership by 0.88% to 1,811,095 units (SEC Form 4)

SVP & CHIEF FINANCIAL OFFICER Sawaf Aziz covered exercise/tax liability with 8,477 units of Ordinary Shares, decreasing direct ownership by 3% to 312,889 units (SEC Form 4)

SVP, DEV & HEAD OF IRE OFFICE Miller Aine covered exercise/tax liability with 10,076 units of Ordinary Shares, decreasing direct ownership by 6% to 150,556 units (SEC Form 4)

$TBPH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Theravance Biopharma downgraded by Leerink Partners with a new price target

BTIG Research initiated coverage on Theravance Biopharma with a new price target

Theravance Biopharma downgraded by Evercore ISI

$TBPH Leadership Updates

Live Leadership Updates

Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors

Irenic Welcomes the Appointment of a Shareholder Representative to Theravance Biopharma's Board of Directors

Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors

Recent Analyst Ratings for
$TBPH

$TBPH
Insider Purchases

$TBPH
Press Releases

$TBPH
Large Ownership Changes

$TBPH
Financials

$TBPH
Market Insights

$TBPH
SEC Filings

$TBPH
Insider Trading

$TBPH
Analyst Ratings

$TBPH
Leadership Updates